- Focus on developing a novel treatment for inflammatory and autoimmune diseases targeting the melanocortin system
- Near-term value inflection points from Phase II development and other corporate activities
- First-in-class compound with unique biology and once-daily dosing designed to have versatility across several indications
- Fortified IP portfolio providing protection until 2042
- Experienced management team and BoD with strong track record in drug development and deal making
- Continually evaluating compelling business development opportunities
Investment Highlights
